Pub Date : 2021-11-01DOI: 10.1136/thorax-2021-btsabstracts.50
R. Chan, C. Kuo, B. Lipworth
{"title":"S44 Bronchodilator response for airway oscillometry in severe eosinophilic asthma","authors":"R. Chan, C. Kuo, B. Lipworth","doi":"10.1136/thorax-2021-btsabstracts.50","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.50","url":null,"abstract":"","PeriodicalId":413592,"journal":{"name":"What goes down, must come up: oscillation, obstruction and lung physiology","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123831296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/thorax-2021-btsabstracts.49
R. Chan, B. Lipworth
{"title":"S43 Repeatability of impulse oscillometry in patients with severe asthma","authors":"R. Chan, B. Lipworth","doi":"10.1136/thorax-2021-btsabstracts.49","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.49","url":null,"abstract":"","PeriodicalId":413592,"journal":{"name":"What goes down, must come up: oscillation, obstruction and lung physiology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121597335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/thorax-2021-btsabstracts.52
A. Shah, N. Shafi, A. Saigal, S. Mandal, M. Lipman, D. Hughes
IP-10) and cytokines (IL-6, IL-1). CS leads to fever, hypotension, coagulopathy, respiratory failure, ARDS, and death. Lenzilumab is a novel Humaneered ® anti-human GM-CSF monoclonal antibody that binds GM-CSF and prevents signaling through its receptor. The LIVE-AIR Phase 3 randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lenzilumab to improve the likelihood of ventilator-free survival (referred to herein as survival without ventilation, SWOV), beyond standard suppor-tive care, in hospitalized subjects with severe COVID-19. Background The hyperinflammatory cytokine storm (CS) of COVID-19 is mediated by GM-CSF leading to release of downstream inflammatory chemokines, cytokines, and markers of systemic inflammation (C-reactive protein, CRP). The LIVE-AIR study demonstrated that lenzilumab, an anti-GM-CSF monoclonal antibody in patients hospitalized with COVID-19, safely improved the likelihood of achieving the primary endpoint, survival without ventilation (SWOV) by 1.54-fold (HR: 1.54; 95%CI: 1.02 – 2.32, p=0.0403) compared with placebo. An exploratory analysis in patients with CRP<150 mg/L and age<85 years was conducted to deter-mine lenzilumab efficacy when administered prior to advanced inflammation.
{"title":"S46 Lung function and pulmonary symptoms in classical and late-onset fabry disease","authors":"A. Shah, N. Shafi, A. Saigal, S. Mandal, M. Lipman, D. Hughes","doi":"10.1136/thorax-2021-btsabstracts.52","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.52","url":null,"abstract":"IP-10) and cytokines (IL-6, IL-1). CS leads to fever, hypotension, coagulopathy, respiratory failure, ARDS, and death. Lenzilumab is a novel Humaneered ® anti-human GM-CSF monoclonal antibody that binds GM-CSF and prevents signaling through its receptor. The LIVE-AIR Phase 3 randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lenzilumab to improve the likelihood of ventilator-free survival (referred to herein as survival without ventilation, SWOV), beyond standard suppor-tive care, in hospitalized subjects with severe COVID-19. Background The hyperinflammatory cytokine storm (CS) of COVID-19 is mediated by GM-CSF leading to release of downstream inflammatory chemokines, cytokines, and markers of systemic inflammation (C-reactive protein, CRP). The LIVE-AIR study demonstrated that lenzilumab, an anti-GM-CSF monoclonal antibody in patients hospitalized with COVID-19, safely improved the likelihood of achieving the primary endpoint, survival without ventilation (SWOV) by 1.54-fold (HR: 1.54; 95%CI: 1.02 – 2.32, p=0.0403) compared with placebo. An exploratory analysis in patients with CRP<150 mg/L and age<85 years was conducted to deter-mine lenzilumab efficacy when administered prior to advanced inflammation.","PeriodicalId":413592,"journal":{"name":"What goes down, must come up: oscillation, obstruction and lung physiology","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130954516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/thorax-2021-btsabstracts.48
J. Feary, T. Kabir, S. Schofield, P. Cullinan
the use of impulse oscillometry (IOS) in of may on the first 203 individuals cohort of We significant bronchodilator response an improvement in forced expiratory volume in one second (FEV1) of 12% and 200mls following administration of inhaled bronchodilator. We also collected information on smoking and self-reported breathlessness using the Dyspnoea-12 questionnaire (maximum score of 36) and explored correlations between different measurements of small airways function. and year of Overall, 32 (16%) had a of asthma (ever), 15 (8%) had evi-dence of significant bronchodilator reversibility and 3 (2%) were taking asthma treatment. The majority (73%) reported no breathless (Dyspnoea-12 score of zero). The mean percent-age predicted pre-bronchodilator FEV1, forced vital capacity (FVC) and forced expiratory flow at 25 – 75% of FVC (FEF25 – 75) were 98%, 102% and 92% respectively using GLI reference equations. The correlation between FEF25 – 75 and frequency dependence of resistance (R5-R20) was (-0.35
{"title":"S42 Correlation of measurement of small airways indices in a population of firefighters","authors":"J. Feary, T. Kabir, S. Schofield, P. Cullinan","doi":"10.1136/thorax-2021-btsabstracts.48","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.48","url":null,"abstract":"the use of impulse oscillometry (IOS) in of may on the first 203 individuals cohort of We significant bronchodilator response an improvement in forced expiratory volume in one second (FEV1) of 12% and 200mls following administration of inhaled bronchodilator. We also collected information on smoking and self-reported breathlessness using the Dyspnoea-12 questionnaire (maximum score of 36) and explored correlations between different measurements of small airways function. and year of Overall, 32 (16%) had a of asthma (ever), 15 (8%) had evi-dence of significant bronchodilator reversibility and 3 (2%) were taking asthma treatment. The majority (73%) reported no breathless (Dyspnoea-12 score of zero). The mean percent-age predicted pre-bronchodilator FEV1, forced vital capacity (FVC) and forced expiratory flow at 25 – 75% of FVC (FEF25 – 75) were 98%, 102% and 92% respectively using GLI reference equations. The correlation between FEF25 – 75 and frequency dependence of resistance (R5-R20) was (-0.35","PeriodicalId":413592,"journal":{"name":"What goes down, must come up: oscillation, obstruction and lung physiology","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116997379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/thorax-2021-btsabstracts.51
C. Slinger, A. Vyas, H. Lever, R. Slinger, J. Silva, C. Prior
S44 Figure 1 Spoken sessions A32 Thorax 2021;76(Suppl 2):A1–A205 on A ril 2, 2022 by gest. P rocted by coright. httphorax.bm jcom / T hrax: frst pulished as 10.113orax-2021-B T S absacts.51 on 8 N ovem er 221. D ow nladed fom Conclusions In assessment for causation of breathlessness, observations of the inspiratory arm of the FVL during MCT may provide clues to the experienced clinician. MCT has potential to be a useful adjunct in the assessment for ILO. However, due to poor inter-rater reliability, further studies are needed to improve our understanding. Further prospective studies are needed, ideally with MCT and concurrent laryngoscopy to further investigate the utility in assessment for ILO. S46 LUNG FUNCTION AND PULMONARY SYMPTOMS IN CLASSICAL AND LATE-ONSET FABRY DISEASE AJ Shah, N Shafi, A Saigal, S Mandal, M Lipman, DA Hughes. Thoracic Department, Royal Free London Foundation NHS Trust, London, UK; UCL Respiratory, London, UK; Haematology Department, Royal Free London NHS Foundation Trust, London,
S44图1口语会话A32胸腔2021;76(增刊2):A1-A205在2022年4月2日。P由赖特保护。httphorax。[jj.com / T hrax]首次发表为10.113orax-2021-B T S摘要。]51在8n / 221。在评估呼吸困难的原因时，观察MCT过程中FVL的吸气臂可以为经验丰富的临床医生提供线索。MCT有可能成为劳工组织评估的有用辅助。然而，由于评估者间信度较差，需要进一步的研究来提高我们的理解。需要进一步的前瞻性研究，理想的是MCT和并发喉镜检查，以进一步研究在国际劳工组织评估中的效用。[46]陈建军，李建军，李建军，等。慢性法布里病的肺功能与肺部症状。英国伦敦皇家自由伦敦NHS信托基金会胸外科;伦敦大学呼吸学院，伦敦，英国;伦敦皇家自由NHS基金会信托血液科，
{"title":"S45 A puff of sugar and a pinch of (speech & language therapy) SALT: is the mannitol challenge test a useful ingredient in the assessment of inducible laryngeal obstruction?","authors":"C. Slinger, A. Vyas, H. Lever, R. Slinger, J. Silva, C. Prior","doi":"10.1136/thorax-2021-btsabstracts.51","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.51","url":null,"abstract":"S44 Figure 1 Spoken sessions A32 Thorax 2021;76(Suppl 2):A1–A205 on A ril 2, 2022 by gest. P rocted by coright. httphorax.bm jcom / T hrax: frst pulished as 10.113orax-2021-B T S absacts.51 on 8 N ovem er 221. D ow nladed fom Conclusions In assessment for causation of breathlessness, observations of the inspiratory arm of the FVL during MCT may provide clues to the experienced clinician. MCT has potential to be a useful adjunct in the assessment for ILO. However, due to poor inter-rater reliability, further studies are needed to improve our understanding. Further prospective studies are needed, ideally with MCT and concurrent laryngoscopy to further investigate the utility in assessment for ILO. S46 LUNG FUNCTION AND PULMONARY SYMPTOMS IN CLASSICAL AND LATE-ONSET FABRY DISEASE AJ Shah, N Shafi, A Saigal, S Mandal, M Lipman, DA Hughes. Thoracic Department, Royal Free London Foundation NHS Trust, London, UK; UCL Respiratory, London, UK; Haematology Department, Royal Free London NHS Foundation Trust, London,","PeriodicalId":413592,"journal":{"name":"What goes down, must come up: oscillation, obstruction and lung physiology","volume":"227 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125792120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/thorax-2021-btsabstracts.53
H. Lever, K. Prior, A. Vyas, C. Slinger
{"title":"S47 Hard to swallow; incidence of oropharyngeal dysphagia in inducible laryngeal obstruction (ILO)","authors":"H. Lever, K. Prior, A. Vyas, C. Slinger","doi":"10.1136/thorax-2021-btsabstracts.53","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.53","url":null,"abstract":"","PeriodicalId":413592,"journal":{"name":"What goes down, must come up: oscillation, obstruction and lung physiology","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121654334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：